Novartis Institutes for BioMedical Research (NIBR) - Articles and news items

Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival

Industry news / 10 October 2016 / Niamh Louise Marriott, Digital Content Producer

The results demonstrate that LEE011 plus letrozole reduced the risk of death or progression by 44%. The combination significantly improved PFS across…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+